EFFICIENCY OF INGARON IN THE TREATMENT OF PATIENTS WITH DESTRUCTIVE PULMONARY BACTERIOLOGICALY PROVEN TUBERCULOSIS
The authors studied the efficiency of Ingaron drug in the intensive phase of the complex treatment of newly diagnosed patients with destructive pulmonary bacterially proven tuberculosis, and the dynamics of clinical and immunological parameters. We examined 60 patients (the clinical trial of the drug was conducted in 30 newly diagnosed patients who received 500 000 IU Ingaron i/m, every other day for a month, in addition to standard therapy). Advantageously, the clinical form was infiltrative, which was diagnosed in 80% of patients in both groups (p> 0.05). After 2 months of intensive phase of treatment, the lung cavities closed in 23.3% of cases, and in 4 months, this figure was 50%. Abacillation occurred in 90% of patients taking Ingaron. A month later, normalization of blood count occurred in 70,0 ± 8,3% (21 of 30). Under the influence of immunomodulation there was noted an increase of CD4 count: up to 40,94 ± 3,11% (p <0.001 for the comparison with the same indicator before treatment). In the group of patients receiving additional Ingaron, CD4 count was 1.7 times greater than the initial level. The developed method of immunomodulating therapy is an essential complement to the anti-TB drugs from the standpoint of pathogenesis. The application of Ingaron in the complex treatment of patients with destructive pulmonary bacterially proven tuberculosis has shown its high efficiency in the intensive phase of chemotherapy, which significantly improves the quality of life of patients.
Maslennikov AA, Obolonkova NI. Efficiency of Ingaron in the treatment of patients with destructive pulmonary bacteriologicaly proven tuberculosis. Research Result. Medicine and Pharmacy Series.2016;2(1):10-16 (In Russian). DOI: 10.18413/2313-8955-2016-2-1-10-16
While nobody left any comments to this publication.
You can be first.
1. Vasilieva I.A., Ergeshov A.E., Samoilova A.G. et al. Long-term Results of Application of Standard Chemotherapy Regimens in Patients with Pulmonary Tuberculosis // Tuberculosis. 2012. № 4. Pp. 3-8.
2. Karpin N.L. Complex Pathogenetic Therapy of Patients with Progressive Destructive Pulmonary Tuberculosis at the Stage of Surgical Treatment (clinical and experimental study): Dis. ... Dr. med. Sciences. M., 2007. 208 p.
3. Komissarova O.G. The Course of the Process and Effectiveness of Treatment in Patients with Drug-resistant Pulmonary Tuberculosis of Different Intensities of Systemic Inflammatory Response Syndrome: Author. Dis. ... Dr. med. Sciences. M., 2011. 48 p.
4. Lysov A.V., Mordyk A.V., Plekhanova M.A. et al. Pathogenetic Therapy of Tuberculosis:. Tutorial. Omsk, 2006. 224 p.
5. The Russian Federation Ministry of Health. On the Improvement of TB Control Activities in the Russian Federation. Order of 21 March 2003 number 109. M., 2003. 347 p.
6. Shashidharamurthy R., Hennigar R.A., Fuchs S. et al. Extravasations and emigration of neutrophils to the inflammatory site depend on the interaction of immune-complex with Fcgamma receptors and can be effectively blocked by decoy Fc-gamma receptors // Blood. 2008. Vol. 111, № 2. Р. 894-904.
7. Torchinsky A., Fein A., Toder V. Immunoteratology: I. MHC involvement in the embryo response to teratogens in mice // Am. J. Reprod. Immunol. 1995. Vol. 34, № 5. Р. 288-298.
8. Mitnick C.D., Shin S.S., Seung K.J. et al. Comprehensive treatment of extensively drug-resistant tuberculosis // N. Engl. J.
Med. 2008. Vol. 359, № 6. Р. 563-574.
9. World Health Organization. Anti-tuberculosis drug resistance in the world: fourth global report. Geneva, 2008.
10. World Health Organization. Global tuberculosis control: epidemiology, strategy, financing. WHO report 2009. Geneva, 2009.
11. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis. Emergency update 2008.